A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC (Galaxy 2)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by Synta Pharmaceuticals Corp.
Sponsor:
Information provided by (Responsible Party):
Synta Pharmaceuticals Corp.
ClinicalTrials.gov Identifier:
NCT01798485
First received: February 4, 2013
Last updated: August 21, 2014
Last verified: August 2014
  Purpose

The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of patients with advanced non-small cell lung cancer.


Condition Intervention Phase
Non-Small-Cell Lung Adenocarcinoma
Non-small Cell Lung Cancer Stage IIIB
Non-small Cell Lung Cancer Stage IV
Non-small Cell Lung Cancer Metastatic
Drug: Arm A: single agent docetaxel
Drug: Arm B: Combination of ganetespib and docetaxel
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced Non-Small-Cell Lung Adenocarcinoma

Resource links provided by NLM:


Further study details as provided by Synta Pharmaceuticals Corp.:

Primary Outcome Measures:
  • Overall survival [ Time Frame: 36 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Progression-free survival [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  • Objective Response Rate [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  • Disease control rate [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  • Duration of response [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  • Symptom improvement [ Time Frame: 36 months ] [ Designated as safety issue: No ]
    Symptom improvement will be evaluated based on patient responses to quality of life questionnaires.

  • Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 36 months ] [ Designated as safety issue: Yes ]
  • Exploratory biomarker analyses [ Time Frame: 36 months ] [ Designated as safety issue: No ]
    Exploratory biomarker analyses will assess correlation between biomarkers and clinical outcome.

  • Emergence of metastatic lesions [ Time Frame: 36 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 850
Study Start Date: March 2013
Estimated Study Completion Date: March 2016
Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Single agent docetaxel Drug: Arm A: single agent docetaxel
Single agent docetaxel 75 mg/m2
Experimental: Combination of ganetespib and docetaxel Drug: Arm B: Combination of ganetespib and docetaxel
ganetespib 150 mg/m2 in combination with docetaxel 75 mg/m2

Detailed Description:

Preliminary signals of clinical activity of ganetespib as a single agent have been observed in patients with advanced NSCLC. A Phase 2b/3 Study (9090-08) was initiated to evaluate the safety and activity of ganetespib in combination with docetaxel vs. docetaxel alone in NSCLC. Study 9090-08 is ongoing. Results from an interim analysis show that the combination has been well tolerated and an encouraging improvement in efficacy, including overall survival(OS) has been observed.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Advanced Stage IIIB or IV NSCLC
  • Eastern Oncology Cooperative Group (ECOG) Performance Status 0 or 1
  • Prior therapy defined as 1 prior systemic therapy for advanced disease
  • Documented disease progression during or following most first line therapy for advanced disease
  • Adequate hematologic, hepatic, renal function

Exclusion Criteria:

  • EGFR mutations
  • ALK translocations
  • Predominantly squamous, adenosquamous or unclear histologic type
  • Active or untreated CNS metastases
  • Active malignancies other than NSCLC within the last 5 years with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin
  • Serious cardiac illness or medical conditions
  • Pregnant or lactating women
  • Uncontrolled intercurrent illness
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01798485

Contacts
Contact: Synta Pharmaceuticals ClinicalTrials.gov Call Center 855-499-9664 9090-14_StudyInfo@SyntaPharma.com

  Hide Study Locations
Locations
United States, Arizona
Synta Pharmaceuticals Investigational Site Recruiting
Tucson, Arizona, United States, 85715
United States, California
Synta Pharmaceuticals Investigational Site Recruiting
Duarte, California, United States, 91010
Synta Pharmaceuticals Investigational Site Recruiting
Hollywood, California, United States, 33021
Synta Pharmaceuticals Investigational Site Recruiting
Los Angeles, California, United States, 90095
Synta Pharmaceuticals Investigational Site Recruiting
Pasadena, California, United States, 91030
Synta Pharmaceuticals Investigational Site Recruiting
Redondo Beach, California, United States, 90277
Synta Pharmaceuticals Investigational Site Recruiting
Sacramento, California, United States, 95817
United States, Florida
Synta Pharmaceuticals Investigational Site Recruiting
Boca Raton, Florida, United States, 33486
Synta Pharmaceuticals Investigational Site Recruiting
Deerfield Beach, Florida, United States, 33442-7753
Synta Pharmaceuticals Investigational Site Recruiting
Miami, Florida, United States, 33176-2149
Synta Pharmaceuticals Investigational Site Recruiting
Tampa, Florida, United States, 33612
United States, Georgia
Synta Pharmaceuticals Investigational Site Recruiting
Atlanta, Georgia, United States, 30322
Synta Pharmaceuticals Investigational Site Recruiting
Marietta, Georgia, United States, 30060-1173
United States, Illinois
Synta Pharmaceuticals Investigational Site Recruiting
Chicago, Illinois, United States, 60637
United States, Maryland
Synta Pharmaceuticals Investigational Site Recruiting
Easton, Maryland, United States, 21601
United States, Massachusetts
Synta Pharmaceuticals Investigational Site Recruiting
Boston, Massachusetts, United States, 02215
Synta Pharmaceuticals Investigational Site Recruiting
Boston, Massachusetts, United States, 02114
United States, Missouri
Synta Pharmaceuticals Investigational Site Recruiting
Bridgeton, Missouri, United States
United States, North Carolina
Synta Pharmaceuticals Investigational Site Recruiting
Chapel Hill, North Carolina, United States, 27599
Synta Pharmaceuticals Investigational Site Recruiting
Charlotte, North Carolina, United States, 28204
Synta Pharmaceuticals Investigational Site Recruiting
Winston-Salem, North Carolina, United States, 27103
United States, Oklahoma
Synta Pharmaceuticals Investigational Site Recruiting
Tulsa, Oklahoma, United States, 74146
United States, Oregon
Synta Pharmaceuticals Investigational Site Recruiting
Portland, Oregon, United States, 97227
United States, Pennsylvania
Synta Pharmaceuticals Investigational Site Recruiting
Pittsburgh, Pennsylvania, United States, 15232
United States, South Dakota
Synta Pharmaceuticals Investigational Site Recruiting
Watertown, South Dakota, United States, 57201
United States, Tennessee
Synta Pharmaceuticals Investigational Site Recruiting
Chattanooga, Tennessee, United States, 37421
United States, Texas
Synta Pharmaceuticals Investigational Site Recruiting
Arlington, Texas, United States, 76012
Synta Pharmaceuticals Investigational Site Recruiting
Dallas, Texas, United States, 75390
Synta Pharmaceuticals Investigational Site Recruiting
Dallas, Texas, United States, 75246
Synta Pharmaceuticals Investigational Site Recruiting
Houston, Texas, United States, 77030
United States, Washington
Synta Pharmaceuticals Investigational Site Recruiting
Everett, Washington, United States, 98201
Synta Pharmaceuticals Investigational Site Recruiting
Spokane Valley, Washington, United States, 99216
Synta Pharmaceuticals Investigational Site Recruiting
Tacoma, Washington, United States, 98405
Austria
Synta Pharmaceuticals Investigational Site Recruiting
Krems, Austria, 3500
Synta Pharmaceuticals Investigational Site Recruiting
Kufstein, Austria, A-6330
Synta Pharmaceuticals Investigational Site Recruiting
Linz, Austria, 4021
Synta Pharmaceuticals Investigational Site Recruiting
Linz, Austria, 4020
Synta Pharmaceuticals Investigational Site Recruiting
Vienna, Austria, 1145
Synta Pharmaceuticals Investigational Site Recruiting
Vienna, Austria, 1140
Synta Pharmaceuticals Investigational Site Recruiting
Wels, Austria, A-4600
Belgium
Synta Pharmaceuticals Investigational Site Recruiting
Brussels, Belgium, 1200
Synta Pharmaceuticals Investigational Site Recruiting
Haine St. Paul, Belgium, 1700
Synta Pharmaceuticals Investigational Site Recruiting
Yvoir, Belgium, 5533
Bosnia and Herzegovina
Synta Pharmaceuticals Investigational Site Recruiting
Banja Luka, Bosnia and Herzegovina, 18000
Synta Pharmaceuticals Investigational Site Recruiting
Banja Luka, Bosnia and Herzegovina, 78000
Synta Pharmaceuticals Investigative Site Recruiting
Sarajevo, Bosnia and Herzegovina, 71000
Synta Pharmaceuticals Investigational Site Recruiting
Sarajevo, Bosnia and Herzegovina, 71000
Synta Pharmaceuticals Investigational Site Recruiting
Tuzla, Bosnia and Herzegovina, 75000
Canada, Quebec
Synta Pharmaceuticals Investigational Site Recruiting
Montreal, Quebec, Canada, H2W 1S6
Canada
Synta Pharmaceuticals Investigational Site Recruiting
Toronto, Canada, MG5 2M9
Croatia
Synta Pharmaceuticals Investigational Site Withdrawn
Osijek, Croatia, 31 000
Synta Pharmaceuticals Investigational Site Recruiting
Zagreb, Croatia, 10 000
Czech Republic
Synta Pharmaceuticals Investigational Site Recruiting
Olomouc, Czech Republic, 775 20
Synta Pharmaceuticals Investigational Site Recruiting
Ostrava, Czech Republic, 708 52
Synta Pharmaceuticals Investigational Site Recruiting
Prague, Czech Republic, 140 59
Synta Pharmaceuticals Investigational Site Recruiting
Prague, Czech Republic, 18001
Synta Pharmaceuticals Investigational Site Recruiting
Prague, Czech Republic, 128 00
France
Synta Pharmaceuticals Investigational Site Recruiting
Creteil, France, 94010
Synta Pharmaceuticals Investigational Site Recruiting
Grenoble, France, 38700
Synta Pharmaceuticals Investigational Site Recruiting
Rennes, France, 35033
Synta Pharmaceuticals Investigational Site Recruiting
Strasbourg, France, 67091
Germany
Synta Pharmaceuticals Investigational Site Recruiting
Bad Nauheim, Germany, D-61231
Synta Pharmaceuticals Investigational Site Recruiting
Cologne, Germany, 51109
Synta Pharmaceuticals Investigational Site Recruiting
Gauting, Germany, 82131
Synta Pharmaceuticals Investigational Site Recruiting
Grosshansdorf, Germany, 22927
Synta Pharmaceuticals Investigational Site Recruiting
Leubeck, Germany, 23538
Synta Pharmaceuticals Investigational Site Recruiting
Mainz, Germany, 55131
Synta Pharmaceuticals Investigational Site Recruiting
Mannheim, Germany, 68167
Synta Pharmaceuticals Investigational Site Recruiting
Offenbach, Germany, 63069
Hungary
Synta Pharmaceuticals Investigational Site Recruiting
Budapest, Hungary, H-1121
Synta Pharmaceuticals Investigational Site Recruiting
Budapest, Hungary, H-1125
Synta Pharmaceuticals Investigative Site Recruiting
Deszk, Hungary, 6772
Synta Pharmaceuticals Investigational Site Recruiting
Szekesfehervar, Hungary, H-8000
Netherlands
Synta Pharmaceuticals Investigational Site Recruiting
Assen, Netherlands, 9401 RK
Synta Pharmaceuticals Investigational Site Recruiting
Harderwijk, Netherlands, 3844DG
Synta Pharmaceuticals Investigational Site Recruiting
Maastricht, Netherlands, 6202
Synta Pharmaceuticals Investigational Site Recruiting
Utrecht, Netherlands, 3543 AZ
Synta Pharmaceuticals Investigational Site Recruiting
Zwolle, Netherlands, 8025 AB
Poland
Synta Pharmaceuticals Investigational Site Withdrawn
Krakow, Poland, 31-115
Synta Pharmaceuticals Investigational Site Recruiting
Krakow, Poland, 31-530
Synta Pharmaceuticals Investigational Site Recruiting
Olsztyn, Poland, 10-357
Synta Pharmaceuticals Investigational Site Recruiting
Poznan, Poland, 60-693
Synta Pharmaceuticals Investigational Site Recruiting
Prabuty, Poland, 82-550
Synta Pharmaceuticals Investigational Site Recruiting
Szczecin, Poland, 70-891
Synta Pharmaceuticals Investigational Site Recruiting
Warsaw, Poland, 02-781
Romania
Synta Pharmaceuticals Investigational Site Recruiting
Bucharest, Romania, 030171
Synta Pharmaceuticals Investigational Site Recruiting
Bucharest, Romania, 022328
Synta Pharmaceuticals Investigational Site Recruiting
Bucharest, Romania, 050098
Synta Pharmaceuticals Investigational Site Recruiting
Cluj Napoca, Romania, 400058
Synta Pharmaceuticals Investigational Site Recruiting
Cluj Napoca, Romania, 400015
Synta Pharmaceuticals Investigational Site Recruiting
Cluj-Napoca, Romania, 400015
Synta Pharmaceuticals Investigational Site Recruiting
Craiova, Romania, 200385
Synta Pharmaceuticals Investigational Site Recruiting
Iasi, Romania, 700483
Synta Pharmaceuticals Investigational Site Recruiting
Timisoara, Romania, 300239
Russian Federation
Synta Pharmaceuticals Investigational Site Active, not recruiting
Chelyabinsk, Russian Federation, 454087
Synta Pharmaceuticals Investigational Site Active, not recruiting
Ekaterinburg, Russian Federation, 620036
Synta Pharmaceuticals Investigational Site Active, not recruiting
Ivanovo, Russian Federation, 153040
Synta Pharmaceuticals Investigational Site Active, not recruiting
Izhevsk, Russian Federation, 426067
Synta Pharmaceuticals Investigational Site Active, not recruiting
Kemerovo, Russian Federation, 650036
Synta Pharmaceuticals Investigational Site Active, not recruiting
Krasnoyarsk, Russian Federation, 660133
Synta Pharmaceuticals Investigational Site Active, not recruiting
Kursk, Russian Federation, 305035
Synta Pharmaceuticals Investigational Site Active, not recruiting
Lipetsk, Russian Federation, 398005
Synta Pharmaceuticals Investigational Site Active, not recruiting
Moscow, Russian Federation, 115478
Synta Pharmaceuticals Investigational Site Withdrawn
Moscow, Russian Federation, 129128
Synta Pharmaceuticals Investigational Site Active, not recruiting
Nizhny Novgorod, Russian Federation, 603081
Synta Pharmaceuticals Investigational Site Active, not recruiting
Novosibirsk, Russian Federation, 630047
Synta Pharmaceuticals Investigational Site Active, not recruiting
Omsk, Russian Federation, 644013
Synta Pharmaceuticals Investigational Site Active, not recruiting
Orel, Russian Federation, 302020
Synta Pharmaceuticals Investigational Site Active, not recruiting
Rostov-on-Don, Russian Federation, 344037
Synta Pharmaceuticals Investigational Site Active, not recruiting
Samara, Russian Federation, 443031
Synta Pharmaceuticals Investigational Site Active, not recruiting
Saransk, Russian Federation, 430032
Synta Pharmaceuticals Investigational Site Active, not recruiting
Sochi, Russian Federation, 354057
Synta Pharmaceuticals Investigational Site Active, not recruiting
St. Petersburg, Russian Federation, 194017
Synta Pharmaceuticals Investigational Site Active, not recruiting
St. Petersburg, Russian Federation, 198255
Synta Pharmaceuticals Investigational Site Active, not recruiting
St. Petersburg, Russian Federation, 197758
Synta Pharmaceuticals Investigational Site Active, not recruiting
Stavropol, Russian Federation, 355047
Synta Pharmaceuticals Investigational Site Withdrawn
Tula, Russian Federation, 300040
Synta Pharmaceuticals Investigational Site Active, not recruiting
Ufa, Russian Federation, 450000
Synta Pharmaceuticals Investigational Site Active, not recruiting
Ufa, Russian Federation, 450054
Serbia
Synta Pharmaceuticals Investigational Site Recruiting
Belgrade, Serbia, 11080
Synta Pharmaceuticals Investigational Site Recruiting
Belgrade, Serbia, 3617-777
Synta Pharmaceuticals Investigational Site Recruiting
Belgrade, Serbia, 11000
Synta Pharmaceuticals Investigational Site Recruiting
Kragujevac, Serbia, 34 000
Synta Pharmaceuticals Investigational Site Recruiting
Nis, Serbia, 18000
Synta Pharmaceuticals Investigational Site Recruiting
Sremska Kamenica, Serbia, 21204
Slovenia
Synta Pharmaceuticals Investigational Site Recruiting
Golnik, Slovenia, 0424
Synta Pharmaceuticals Investigational Site Recruiting
Ljubljana, Slovenia, 1000
Spain
Synta Pharmaceuticals Investigational Site Recruiting
Badalona, Spain, 08916
Synta Pharmaceuticals Investigational Site Recruiting
Barcelona, Spain, 08035
Synta Pharmaceuticals Investigational Site Recruiting
Madrid, Spain, 28040
Synta Pharmaceuticals Investigational Site Recruiting
Madrid, Spain, 28034
Synta Pharmaceuticals Investigational Site Recruiting
Madrid, Spain, 28041
Synta Pharmaceuticals Investigational Site Recruiting
Madrid, Spain, 28050
Synta Pharmaceuticals Investigational Site Recruiting
Madrid, Spain, 28223
Synta Pharmaceuticals Investigational Site Recruiting
Valencia, Spain, 460026
Ukraine
Synta Pharmaceuticals Investigational Site Active, not recruiting
Cherkasy, Ukraine, 18009
Synta Pharmaceuticals Investigational Site Active, not recruiting
Chernivtsi, Ukraine, 58013
Synta Pharmaceuticals Investigational Site Active, not recruiting
Dnepropetrovsk, Ukraine, 49102
Synta Pharmaceuticals Investigational Site Active, not recruiting
Donetsk, Ukraine, 83092
Synta Pharmaceuticals Investigational Site Active, not recruiting
Donetsk, Ukraine, 83087
Synta Pharmaceuticals Investigational Site Active, not recruiting
Ivano-Frankivsk, Ukraine, 76000
Synta Pharmaceuticals Investigative Site Active, not recruiting
Kharkiv, Ukraine, 61070
Synta Pharmaceuticals Investigational Site Active, not recruiting
Khmelnytskyi, Ukraine, 29009
Synta Pharmaceuticals Investigational Site Active, not recruiting
Kirovohrad, Ukraine, 25011
Synta Pharmaceuticals Investigational Site Active, not recruiting
Kryvyi Rih, Ukraine, 50048
Synta Pharmaceuticals Investigational Site Active, not recruiting
Kyiv, Ukraine, 03115
Synta Pharmaceuticals Investigational Site Active, not recruiting
Makiivka, Ukraine, 86120
Synta Pharmaceuticals Investigational Site Active, not recruiting
Poltava, Ukraine, 36011
Synta Pharmaceuticals Investigational Site Active, not recruiting
Simferopol, Ukraine, 95023
Synta Pharmaceuticals Investigational Site Active, not recruiting
Sumy, Ukraine, 40022
Synta Pharmaceuticals Investigational Site Active, not recruiting
Uzhhorod, Ukraine, 88014
Synta Pharmaceuticals Investigational Site Active, not recruiting
Vinnytsia, Ukraine, 21021
United Kingdom
Synta Pharmaceuticals Investigational Site Recruiting
Sutton, Surrey, United Kingdom, SM2 5PT
Synta Pharmaceuticals Investigational Site Recruiting
Cardiff, United Kingdom, CF14 2TL
Synta Pharmaceuticals Investigational Site Recruiting
Edinburgh, United Kingdom, EH4 2XU
Synta Pharmaceuticals Investigational Site Recruiting
Leicester, United Kingdom, LEI 5WW
Synta Pharmaceuticals Investigational Site Recruiting
London, United Kingdom, SW3 6JJ
Synta Pharmaceuticals Investigational Site Recruiting
London, United Kingdom, SE1 9RT
Synta Pharmaceuticals Investigational Site Recruiting
Nottingham, United Kingdom, NG5 1PB
Synta Pharmaceuticals Investigational Site Recruiting
Southampton, United Kingdom, SO16 6YD
Sponsors and Collaborators
Synta Pharmaceuticals Corp.
  More Information

No publications provided

Responsible Party: Synta Pharmaceuticals Corp.
ClinicalTrials.gov Identifier: NCT01798485     History of Changes
Other Study ID Numbers: 9090-14
Study First Received: February 4, 2013
Last Updated: August 21, 2014
Health Authority: United States: Food and Drug Administration
Austria: Austrian Agency for Health and Food Safety
Belgium: Federal Agency for Medicinal Products and Health Products
Bosnia: Federal Ministry of Health
Canada: Health Canada
Croatia: Ministry of Health and Social Care
Czech Republic: State Institute for Drug Control
France: Agence Nationale de Sécurité du Médicament et des produits de santé
Germany: Federal Institute for Drugs and Medical Devices
Hungary: National Institute of Pharmacy
Italy: Ministry of Health
Netherlands: Medicines Evaluation Board (MEB)
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Romania: National Medicines Agency
Russia: Pharmacological Committee, Ministry of Health
Serbia and Montenegro: Agency for Drugs and Medicinal Devices
Slovenia: Agency for Medicinal Products and Medical Devices of the Republic of Slovenia
Spain: Agencia Española de Medicamentos y Productos Sanitarios
Ukraine: State Pharmacological Center - Ministry of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Adenocarcinoma
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Docetaxel
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 28, 2014